Compositions and methods for inhibiting expression of coagulation factor xi (FXI)

TW202627092APending Publication Date: 2026-07-01SHANGHAI ARGO BIOPHARMACEUTICAL CO LTD

0 Cites 0 Cited by

Patent Information

Application Number: TW114144010
Authority / Receiving Office: TW · TW
Patent Type: Applications
Current Assignee / Owner
Filing Date: 2025-11-12
Publication Date: 2026-07-01

Application Information

Patent Timeline

12 Nov 2025

Application

TW114144010

01 Jul 2026

Publication

TW202627092A

IPC: C12N15/113; A61K31/713; A61P7/02

Inventors: 舒東旭; 邵鵬程

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

Compositions and methods useful to inhibiting the expression of Plasma Coagulation Factor XI (FXI) gene and for treatment of FXI -associated diseases and conditions are provided. Provided are FXI dsRNA agents, FXI antisense polynucleotide agents, compositions comprising FXI dsRNA agents, and compositions comprising FXI antisense polynucleotide agents that can be used to inhibiting FXI expression in cells and subjects.

Need to check novelty before this filing date? Find Prior Art